Movement Alert｜Vertex Pharmaceuticals Falls 3.06% in Regular Trading, FDA Accepts BLA for Povetacicept in IgA Nephropathy

Market Focus06-03

On June 3, Vertex Pharmaceuticals fell 3.06% in regular trading, trading at $425.24/share, with trading volume of $180 million.

On the news front, the company recently announced that the U.S. Food and Drug Administration has formally accepted its Biologics License Application (BLA) for candidate drug Povetacicept in the treatment of immunoglobulin A nephropathy (IgA nephropathy), seeking an accelerated approval pathway. The accelerated approval pathway is a mechanism established by the FDA to address serious diseases with unmet medical needs, aimed at expediting access to important therapies. If ultimately approved, Povetacicept could provide a new treatment option for IgA nephropathy patients.

Vertex Pharmaceuticals is a global biotechnology company that has developed approved therapies for conditions including cystic fibrosis and sickle cell disease, while continuing to advance clinical programs in IgA nephropathy, Type 1 diabetes, and other therapeutic areas.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1110535400?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 01:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110535400","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Vertex Pharmaceuticals Falls 3.06% in Regular Trading, FDA Accepts BLA for Povetacicept in IgA Nephropathy","media":"Market Focus","content":"<p><p>On June 3, Vertex Pharmaceuticals fell 3.06% in regular trading, trading at $425.24/share, with trading volume of $180 million.</p><p>On the news front, the company recently announced that the U.S. Food and Drug Administration has formally accepted its Biologics License Application (BLA) for candidate drug Povetacicept in the treatment of immunoglobulin A nephropathy (IgA nephropathy), seeking an accelerated approval pathway. The accelerated approval pathway is a mechanism established by the FDA to address serious diseases with unmet medical needs, aimed at expediting access to important therapies. If ultimately approved, Povetacicept could provide a new treatment option for IgA nephropathy patients.</p><p>Vertex Pharmaceuticals is a global biotechnology company that has developed approved therapies for conditions including cystic fibrosis and sickle cell disease, while continuing to advance clinical programs in IgA nephropathy, Type 1 diabetes, and other therapeutic areas.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Vertex Pharmaceuticals Falls 3.06% in Regular Trading, FDA Accepts BLA for Povetacicept in IgA Nephropathy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Vertex Pharmaceuticals Falls 3.06% in Regular Trading, FDA Accepts BLA for Povetacicept in IgA Nephropathy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-03 01:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 3, Vertex Pharmaceuticals fell 3.06% in regular trading, trading at $425.24/share, with trading volume of $180 million.</p><p>On the news front, the company recently announced that the U.S. Food and Drug Administration has formally accepted its Biologics License Application (BLA) for candidate drug Povetacicept in the treatment of immunoglobulin A nephropathy (IgA nephropathy), seeking an accelerated approval pathway. The accelerated approval pathway is a mechanism established by the FDA to address serious diseases with unmet medical needs, aimed at expediting access to important therapies. If ultimately approved, Povetacicept could provide a new treatment option for IgA nephropathy patients.</p><p>Vertex Pharmaceuticals is a global biotechnology company that has developed approved therapies for conditions including cystic fibrosis and sickle cell disease, while continuing to advance clinical programs in IgA nephropathy, Type 1 diabetes, and other therapeutic areas.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRTX","symbol_name":"福泰制药","start_time":0,"source_url":"","article_id":"1110535400","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110535400","pubTimestamp":1780422490,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 3, Vertex Pharmaceuticals fell 3.06% in regular trading, trading at $425.24/share, with trading volume of $180 million.On the news front, the company recently announced that the U.S. Food and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRTX":"福泰制药"},"translate_title":"动静快讯|Vertex制药常规交易跌3.06%FDA接受Povetacicept治疗IgA肾病的BLA","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRTX":1},"content_text":"On June 3, Vertex Pharmaceuticals fell 3.06% in regular trading, trading at $425.24/share, with trading volume of $180 million.On the news front, the company recently announced that the U.S. Food and Drug Administration has formally accepted its Biologics License Application (BLA) for candidate drug Povetacicept in the treatment of immunoglobulin A nephropathy (IgA nephropathy), seeking an accelerated approval pathway. The accelerated approval pathway is a mechanism established by the FDA to address serious diseases with unmet medical needs, aimed at expediting access to important therapies. If ultimately approved, Povetacicept could provide a new treatment option for IgA nephropathy patients.Vertex Pharmaceuticals is a global biotechnology company that has developed approved therapies for conditions including cystic fibrosis and sickle cell disease, while continuing to advance clinical programs in IgA nephropathy, Type 1 diabetes, and other therapeutic areas.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1110535400","isCrawlerRequest":true}